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ABSTRACT 
The low bioavailability and short half-life of Metformin hydrochloride (MH) make the development of sustained-release forms desirable. 
Present work involves preparation and optimization of sustained release matrix tablet of MH by direct compression method usin g HPMC K 100 
and ethyl cellulose as a matrix forming polymer. Avicel was added as a direct compaction vehicle to improve the compaction behavior of 
Metformin which otherwise exhibits poor compaction behavior which again is further increased by its relatively high dose. Hydrophilic matrix 
of HPMC alone resulted in initial burst of Metformin release, however when combined with ethyl cellulose drug release was slowed down and 
thereafter it became optimal at particular concentration of polymers.  
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INTRODUCTION 
In recent years, hydrophilic matrices are becoming popular 
in controlling the release of soluble drugs from solid dosage 
forms. These systems appear to be one of the most attractive 
approaches from an economic as well as from the process 
development points of view. The use of mixtures of polymers 
represents a potential way of achieving required release 
properties. Mixtures of different nonionic cellulose ethers 
have been used to give different viscous efficiencies1.  
The most widely used polymer for hydrophilic matrices is 
hydroxypropyl methylcellulose (HPMC). This polymer is 
considered among the water-soluble polymers. Ethyl 
cellulose (EC) is considered as a water insoluble polymer due 
to the hydrophobic substituents (ethyl-). This polymer has 
been used mainly to form films for the manufacture of oral 
extended release dosage forms like granules, pellets, 
microcapsules and film tablets. A second polymer like 
hydroxypropyl cellulose has been admixed to change the 
release properties by providing hydrated channels for drug 
release. Mixtures of different proportions of polymers with 
different permeation characteristics could provide a wide 
range of release rates of a drug by changing the diffusivity of 
the drug through a polymer barrier2, 3. 
Metformin hydrochloride is the first line drug of choice for 
the treatment of type II diabetes, especially, in overweight 
and obese people. Metformin helps to improve 
hyperglycemia primarily by suppressing glucose production 
by the liver (hepatic gluconeogenesis). The conventional 
form of Metformin tablets have been found to have many 
side effects such as gastrointestinal upset, including diarrhea, 
cramps, nausea & vomiting. In order to reduce the above 
mentioned side effects and to enhance patient compliances, 
sustained release formulation of Metformin was developed. 
Numerous studies have been reported in literature 
investigating the HPMC matrices to control the release of 
variety of drug4, 5. 
In present study an attempt has been made, to formulate the 
Sustained release matrix tablets of Metformin Hydrochloride 
and tested for controlled delivery of drug using hydrophilic 
matrix polymer HPMC in combination with hydrophobic 
ethyl cellulose, resulting in reduction in the dosing frequency 
of Metformin and there by its dose related side effects. 
MATERIALS & METHODS  
Materials: Metformin hydrochloride, HPMC, Ethyl Cellulose, 
Avicel (Microcrystalline cellulose), Magnesium Stearate, Talc. 
Preparation of sustained release tablet of Metformin 
hydrochloride: 
Sustained release matrix tablets containing 500 mg 
Metformin hydrochloride were prepared by a direct 
compression method. All ingredients except talc and 
magnesium stearate were passed through 60 mesh and 
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mixed thoroughly in a polybag for few minutes. Thereafter 
talc and magnesium stearate were passed through 100 mesh 
to break the clumps and then added to previous mixture in 
polybag for not more than 5 minutes. The mixture is then 
compressed using 8 station rotary tablet press at a constant 
compression force. Different batches were designed in group 
of three depending upon dissolution pattern of the previous 
batch.
 
Table 1: Formulation and composition of SR tablet of MH. 
Ingredients Batch No 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
MH 500 500 500 500 500 500 500 500 500 
HPMC 150 170 190 150 150 150 170 190 210 
EC 10 10 10 20 30 40 30 30 30 
Avicel 150 150 150 100 100 100 100 100 100 
MS 9 9 9 9 9 9 9 9 9 
Talc 9 9 9 9 9 9 9 9 9 
MH-Metformin hydrochloride, HPMC- hydroxyl propyl methyl cellulose, EC- ethl cellulose, Avicel- Microcrystalline cellulose, 
MS- magnesium stearate. 
Evaluation of powder properties   6, 7, 8 : 
The powder mixture obtained from all the batches were 
evaluated for their physicochemical properties.The angle of 
repose (α) was determined by the static funnel method and 
calculated using the formula: 
tan θ = h/r  
Bulk density (BD) was measured by ﬁlling a preweighed 100 
ml glass cylinder to its capacity with the granules and then 
weighing it. The tap density (TD) was calculated by dividing 
the ﬁll weight of the powder by its new reduced volume after 
tapping it 100 times using a tap density apparatus. The 
compressibility index (CI) and Hausner’s ratio (HR) was 
measured by USP method I using a graduated cylinder. 
Results are shown in Table 2. 
Evaluation of compressed tablets 5, 6, 7, 8: 
Prepared tablets were evaluated for Thickness, hardness, 
friability, weight variation, disintegration and dissolution. 
Weight variation was performed by weighing 20 tablets 
individually, taking average weight and comparing individual 
weight with the average weight. Hardness of randomly 
selected tablets was determined by using Erweka hardness 
tester and was measured in Newtons. Friability was 
determined by first weighing 10 tablets before placing in 
Roche friabilator, which was then rotated for 4 minutes at 25 
rpm. After dusting tablets were reweighed. 
In-Vitro Dissolution test: 
In-vitro dissolution studies were carried out using USP XXI 
Dissolution Test Apparatus Type II at 75 rpm. Dissolution 
test was carried out for the period of 12 hours using 
Phosphate Buffer (pH-6.8). 5ml sample was withdrawn at 
predetermined time interval up to 12 hours and replaced 
with same volume of fresh dissolution medium. The 
withdrawn samples were analyzed by SHIMADZU UV 
spectrophotometer at 233 nm using Phosphate Buffer as a 
blank. Percentage cumulative drug release was calculated 9, 
10, 11. 
RESULTS AND DISCUSSION 
Pre compression parameters:  
 
Table 2: Powder properties of different formulations 
Formulation Angle of 
repose 
Bulk density Tapped 
density 
Carr’s 
Index 
Hausner’s 
ratio 
F1 39.23 0.523 0.641 18.4 1.22 
F2 35.41 0.582 0.672 15.4 1.15 
F3      32.17 0.611 0.685 12.1 1.12 
F4 37.15 0.489 0.575 14.9 1.17 
F5 40.21 0.496 0.548 10.4 1.10 
F6 38.12 0.521 0.609 14.4 1.16 
F7 36.57 0.539 0.621 13.2 1.15 
F8 39.48 0.512 0.598 16.7 1.16 
F9 33.27 0.513 0.642 20.0 1.25 
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Post compression parameters: 
Table 3: Tablet properties of Metformin hydrochloride. 
Formulation Average 
weight(mg) 
Thickness(mm) % drug 
content 
Hardness(N) % Friability 
F1 830 5.42 99.6 157 0.27 
F2 849 5.48 99.3 163 0.29 
F3 872 5.67 98.3 169 0.33 
F4 787 5.13 97.5 139 0.21 
F5 803 5.23 101.3 146 0.23 
F6 814 5.32 103.2 148 0.27 
F7 820 5.36 99.8 147 0.31 
F8 843 5.41 98.7 158 0.29 
F9 861 5.56 98.4 160 0.22 
 
In-vitro dissolution studies: 
Table 4: Cumulative % Drug Release (%CDR) 
Time(h
rs) 
                            Cumulative %  Drug Release (% CDR) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 34.1 33.6 29.4 23.8 18.9 9.6 17.1 19.4 16.3 
2 57.4 53.6 49.3 39.7 25.6 13.5 23.5 24.1 19.2 
4 77.5 64.3 59.6 53.6 41.1 27.5 40.3 38.4 33.8 
6 87.3 81.2 75.6 87.2 54.7 38.8 48.6 45.6 41.9 
8 96.8 92.8 88.5 89.3 76.3 59.7 71.9 69.4 56.7 
12 99.1 98.7 97.5 101.2 98.7 85.1 99.3 97.8 87.6 
 
 
Figure 1: In-vitro dissolution profile F1-F3. 
 
Figure 2: In-vitro dissolution profile F4-F6. 
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Figure 3: In-vitro dissolution profile F7-F9. 
Metformin release profiles from matrix tablet can be 
considered as being composed of two parts. The first part is 
the dissolution during the process for the establishment of a 
fully hydrated gel layer and the second part is the 
dissolution through this hydrated gel layer. At the beginning, 
the matrix tablet allows the free dissolution of the 
Metformin directly in contact with the dissolution medium. 
After the transition point, in a time between 1.2 and 2.6 h, 
the second phase controlled by the fully hydrated gel layer. 
In this phase, the Metformin release goes on mainly by 
diffusion through the water filled pores. 
Formulation F1, F2, F3 showed burst of Metformin release 
(57%, 53% & 49% after 2 hours). This can be attributed to 
time taken by HPMC to form fully hydrated gel, during this 
time there was no control on drug release although EC was 
present but its concentration seemed insufficient. This effect 
seemed to be elevated by Avicel, which also has disintegrant 
properties due to its capillary structure. Water penetrated 
through these capillary pores of Avicel and dissolved the 
drug faster, which resulted in initial burst of drug release. 
Even after increasing the concentration of HPMC in F2 and 
F3 (170mg & 190mg respectively), there was still little 
improvement in controlling the initial burst of drug release. 
Once the hydrated matrix of HPMC was formed the drug 
release was slowed down but still it was relatively faster 
(87%, 83%, 82% after 6 hours) 12, 13. 
On the basis of these results, in the next three batches 
concentration of Avicel was reduced to minimize its 
disintegration effects and EC concentration was increased to 
control the initial drug release until the formation of fully 
hydrated matrix of HPMC. After these changes F4, F5 & F6 
showed relatively lower initial burst of drug release (23%, 
19%, 9% respectively after one hour), this may be due to 
incorporation of EC. Hydrophobic nature of EC prevented 
the penetration of the solvent molecules inside the tablet 
core, leading to reduced diffusion of the drug from the 
matrix. This effect was highest in F6 in which 40mg EC was 
added. Once the HPMC matrix was formed drug release was 
fairly uniform but still it was relatively faster. Therefore in 
the next three batches optimum concentration of EC was 
taken as 30mg and was kept constant while concentration of 
HPMC was varied to get more uniform drug release 
especially after six hours of dissolution. 
Finally, F7, F8, F9 showed considerably uniform drug release 
(Table 4), although F9 was too slow in drug release.  
 
CONCLUSION 
It can be concluded that a combination of hydrophilic and 
hydrophobic polymer can be used for extending the release 
of Metformin hydrochloride for the period of 12 hours. 
Initially erosion and thereafter Diffusion might be the 
mechanism for the drug release from hydrophilic and 
hydrophobic polymer based matrix tablets. Optimized 
formulation containing HPMC and EC had successfully 
sustained the drug release up to 12 hours. Thus the 
sustained release tablet of Metformin hydrochloride can be 
formulated, evaluated and found to be suitable candidate for 
prolonging the release of Metformin hydrochloride. 
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